AstraZeneca FDA approval for breast-cancer drug supports sentiment
Citi says AstraZeneca’s U.S. Food and Drug Administration approval for breast-cancer drug Etcamah may matter more for investor sentiment than near-term revenue. The approval points to a relatively modest opportunity versus the larger market.